Nadir platelet and neutrophil counts during the course of PEG-IFN α-2b plus ribavirin combination therapy can be predicted by the values at week one: Towards achieving better efficacy

Many patients have to discontinue treatment with pegylated interferon ribavirin (PEG-IFNα-2b/RBV) combination therapy due to haematological side effects such as thrombocytopenia after the start of combination therapy, and the drop in sustained virological response rates due to the cessation of therapy is problematic. The present study, therefore, examined 121 hepatitis C patients who underwent PEG-IFNα-2b/RBV combination therapy at Nihon University Itabashi Hospital from April 2003 to March 2009, fitted them into a multiple regression model with the lowest platelet level up to 3 weeks after the start of treatment as the objective variable and patient demographics before the start of treatment as the explanatory variable, and prepared a predictive model of the lowest platelet level. Using this, a predictive model of the lowest platelet level (R 2 = 0.70, p <0.0001) was prepared for (1) the dose of PEG-IFNα-2b (µg/kg) per 1 kg of body weight, (2) platelet count (×10 9 /L), and (3) ALP (IU/L) as a variable. This predictive model is not only expected to make it easier to avoid treatment discontinuation, but also to call attention to any hemorrhagic tendency early on and allow measures to be taken, and should lead to qualitative improvement in treatment.

show abstract

Prediction of the Lowest Level of Thrombocytopenia to Avoid Thrombocytopenia-related Treatment Discontinuation in PEG-IFNα-2b/RBV Combination Therapy

Suzuki

Koinuma

Hoshino

et al. 2012

Jpn. J. Pharm. Health Care Sci.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Nadir platelet and neutrophil counts during the course of PEG-IFN α-2b plus ribavirin combination therapy can be predicted by the values at week one: Towards achieving better efficacy

Cited by 1 publication

References 14 publications

Prediction of the Lowest Level of Thrombocytopenia to Avoid Thrombocytopenia-related Treatment Discontinuation in PEG-IFNα-2b/RBV Combination Therapy

Prediction of the Lowest Level of Thrombocytopenia to Avoid Thrombocytopenia-related Treatment Discontinuation in PEG-IFNα-2b/RBV Combination Therapy

Contact Info

Product

Resources

About